Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Gene based delivery of immunoglobulins promises to safely and durably provide protective immunity to individuals at risk of acquiring infectious diseases such as HIV. We used a rhesus macaque animal model to optimize delivery of naturally-arising, autologous anti-SIV neutralizing antibodies expressed by Adeno-Associated Virus 8 (AAV8) vectors. Vectored transgene expression was confirmed by quantitation of target antibody abundance in serum and mucosal surfaces. We tested the expression achieved at varying doses and numbers of injections. Expression of the transgene reached a saturation at about 2 x 10(12) AAV8 genome copies (gc) per needle-injection, a physical limitation that may not scale clinically into human trials. In contrast, expression increased proportionately with the number of injections. In terms of anti-drug immunity, anti-vector antibody responses were universally strong, while those directed against the natural transgene mAb were detected in only 20% of animals. An anti-transgene antibody response was invariably associated with loss of detectable plasma expression of the antibody. Despite having atypical glycosylation profiles, transgenes derived from AAV-directed muscle cell expression retained full functional activity, including mucosal accumulation, in vitro neutralization, and protection against repeated limiting dose SIVsmE660 swarm challenge. Our findings demonstrate feasibility of a gene therapy-based passive immunization strategy against infectious disease, and illustrate the potential for the nonhuman primate model to inform clinical AAV-based approaches to passive immunization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Self-citationHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationLynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Self-citationHuman Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Self-citationVan Voorhis, W. C., Adams, J. H., Adelfio, R., Ahyong, V., Akabas, M. H., Alano, P., Alday, A., Alemán Resto, Y., Alsibaee, A., Alzualde, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005763 · Cited by 435
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Self-citationImprovement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Self-citationThe Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Self-citationModulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
Self-citationIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Reed Clark, K. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 298
Self-citationPassive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/ker124 · Cited by 256
VRC 602 Study Team, Ledgerwood, J. E., Coates, E. E., Yamshchikov, G., Saunders, J. G., Holman, L., Enama, M. E., DeZure, A., Lynch, R. M., Gordon, I., et al. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12692 · Cited by 247
Self-citationGene Therapy for Aromatic l -Amino Acid Decarboxylase Deficiency
Hwu, W.-L., Muramatsu, S.-I., Tseng, S.-H., Tzen, K.-Y., Lee, N.-C., Chien, Y.-H., Snyder, R. O., Byrne, B. J., Tai, C.-H., & Wu, R.-M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003640 · Cited by 246
Pegu, A., Yang, Z.-Y., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008992 · Cited by 242
Self-citationGaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G., Saunders, J. G., Holman, L. A., Gordon, I., Plummer, S., Hendel, C. S., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 241
Self-citationEvolving trends in mAb production processes
Shukla, A. A., Wolfe, L. S., Mostafa, S. S., & Norman, C. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10061 · Cited by 239
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
Balazs, A. B., Ouyang, Y., Hong, C. M., Chen, J., Nguyen, S. M., Rao, D. S., An, D. S., & Baltimore, D. (2014) · Nature Medicine · doi:10.1038/nm.3471 · Cited by 237
Self-citationLi, H., Wang, S., Kong, R., Ding, W., Lee, F.-H., Parker, Z., Kim, E., Learn, G. H., Hahn, P., Policicchio, B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606636113 · Cited by 222
Self-citationStroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Brenner, S. (2000) · Science · doi:10.1126/science.287.5461.2173 · Cited by 180
Antibody therapies for the prevention and treatment of viral infections
Salazar, G., Zhang, N., Fu, T.-M., & An, Z. (2017) · npj Vaccines · doi:10.1038/s41541-017-0019-3 · Cited by 173
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination
Mahan, A. E., Jennewein, M. F., Suscovich, T. J., Dionne, K., Tedesco, J., Chung, A. W., Streeck, H., Pau, M. G., Schuitemaker, H., Francis, D., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005456 · Cited by 169
Self-citationMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Paulk, N. K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A. P., Haft, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.021 · Cited by 161
Self-citationAdhikari, R. P., Ajao, A. O., Aman, M. J., Karauzum, H., Sarwar, J., Lydecker, A. D., Johnson, J. K., Nguyen, C., Chen, W. H., & Roghmann, M.-C. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis462 · Cited by 144
Use of broadly neutralizing antibodies for HIV ‐1 prevention
Pegu, A., Hessell, A. J., Mascola, J. R., & Haigwood, N. L. (2017) · Immunological Reviews · doi:10.1111/imr.12511 · Cited by 142
Self-citationBroad protection against influenza infection by vectored immunoprophylaxis in mice
Balazs, A. B., Bloom, J. D., Hong, C. M., Rao, D. S., & Baltimore, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2618 · Cited by 127
Self-citationAllez, M. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95055-5 · Cited by 125
Monoclonal Antibodies for Emerging Infectious Diseases — Borrowing from History
Marston, H. D., Paules, C. I., & Fauci, A. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1802256 · Cited by 125
Saunders, K. O., Wang, L., Joyce, M. G., Yang, Z.-Y., Balazs, A. B., Cheng, C., Ko, S.-Y., Kong, W.-P., Rudicell, R. S., Georgiev, I. S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00908-15 · Cited by 122
Self-citationDNA vaccine strategies: candidates for immune modulation and immunization regimens
Doria‐Rose, N. A. (2003) · Methods · doi:10.1016/s1046-2023(03)00135-x · Cited by 116
Saunders, K. O., Pegu, A., Georgiev, I. S., Zeng, M., Joyce, M. G., Yang, Z.-Y., Ko, S.-Y., Chen, X., Schmidt, S. D., Haase, A. T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00210-15 · Cited by 104
Self-citationFuchs, S. P., Martinez-Navio, J. M., Piatak, M., Lifson, J. D., Gao, G., & Desrosiers, R. C. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005090 · Cited by 99
Self-citationJacobson, J. M., Thompson, M. A., Lalezari, J. P., Saag, M. S., Zingman, B. S., D’Ambrosio, P., Stambler, N., Rotshteyn, Y., Marozsan, A. J., Maddon, P. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/652190 · Cited by 96
Recent Insights into the HIV/AIDS Pandemic
Becerra, J. C., Bildstein, L. S., & Gach, J. S. (2016) · Microbial Cell · doi:10.15698/mic2016.09.529 · Cited by 94
Salmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
Modulating Antibody Functionality in Infectious Disease and Vaccination
Gunn, B. M., & Alter, G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.09.002 · Cited by 79
Self-citationThe Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies
Rompay, K. K. A. V. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0234 · Cited by 70
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability
Mason, R. D., Welles, H. C., Adams, C., Chakrabarti, B. K., Gorman, J., Zhou, T., Nguyen, R., O'Dell, S. J., Lusvarghi, S., Bewley, C. A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005537 · Cited by 69
Self-citationSparrow, E. G., Friede, M., Sheikh, M., Torvaldsen, S., & Newall, A. T. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.08.057 · Cited by 68
Kverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M., & Nielsen, C. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424674 · Cited by 60
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 57
Self-citationGreig, J. A., Peng, H., Ohlstein, J., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S.-J., Bell, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112268 · Cited by 55
Macaca mulatta,fascicularisandnemestrinain AIDS vaccine development
Baroncelli, S., Negri, D. R. M., Michelini, Z., & Cara, A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.9.1419 · Cited by 52
van Lieshout, L. P., Soule, G., Sorensen, D., Frost, K. L., He, S., Tierney, K. J., Safronetz, D., Booth, S. A., Kobinger, G., Qiu, X., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix644 · Cited by 49
Antibody gene transfer for HIV immunoprophylaxis
Balazs, A. B., & West, A. P. (2013) · Nature Immunology · doi:10.1038/ni.2480 · Cited by 40
Self-citationVectored antibody gene delivery for the prevention or treatment of HIV infection
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000145 · Cited by 37
Self-citationMiranda, L. R., Duval, M., Doherty, H., Seaman, M. S., Posner, M. R., & Cavacini, L. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7132 · Cited by 35
Using nonhuman primates to model HIV transmission
Fennessey, C. M., & Keele, B. F. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328361cfff · Cited by 33
Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency
Zwagerman, N. T., & Richardson, R. M. (2012) · Neurosurgery · doi:10.1227/01.neu.0000419706.72039.5c · Cited by 32
Engineering humoral immunity as prophylaxis or therapy
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.014 · Cited by 27
Self-citationParsimonious Determination of the Optimal Infectious Dose of a Pathogen for Nonhuman Primate Models
Roederer, M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005100 · Cited by 15
Self-citationA cure for HIV: what will it take?
Ananworanich, J., & Mellors, J. W. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000125 · Cited by 9
Generating Monoclonal AntibodiesPreprint
Greenfield, E. A. (2022) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top103036 · Cited by 6
Simian-Human Immunodeficiency Viruses and Their Impact on Non-Human Primate Models for AIDS
Lara, E., Srinivasan, P., & James, M. R. (2012) · InTech eBooks · doi:10.5772/53556 · Cited by 5
AAV-Expressed eCD4-Ig Provides Durable Protection From Multiple SHIV Challenges
Church, J. A. (2015) · PEDIATRICS · doi:10.1542/peds.2015-2776ccccc · Cited by 5
Generating Monoclonal Antibodies
Zipser, B., & Schley, C. (2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429277634-5 · Cited by 4
Research works printed but not linked: 2
- D Gaudet, 2013, Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene Ther. Macmillan Publishers Limited, 20, 361
- KO Saunders, 2015, Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection, J Virol, 89, 5895, 10.1128/JVI.00210-15 · DOI · Paper page
Cited by
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In one study, re-administration of AAV8 in NHP did not result in increased transgene expression, but increased anti-AAV antibody levels were observed [75].”
BackgroundPegu, A., Borate, B. R., Huang, Y., Pauthner, M. G., Hessell, A. J., Jülg, B. D., Doria‐Rose, N. A., Schmidt, S. D., Carpp, L. N., Cully, M. D., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.014 · Cited by 122
Self-citationCasazza, J. P., Cale, E. M., Narpala, S., Yamshchikov, G. V., Coates, E. E., Hendel, C. S., Novik, L., Holman, L. A., Widge, A. T., Apte, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01762-x · Cited by 91
Self-citationAdvancements in mRNA Encoded Antibodies for Passive Immunotherapy
Deal, C. E., Carfí, A., & Plante, O. J. (2021) · Vaccines · doi:10.3390/vaccines9020108 · Cited by 91
“Dose escalation studies demonstrated increasing serum concentrations of ZIKV-117 as the dose escalated to 10 μg of mRNA, after which there was no significant increase, likely due to saturation of protein production from cells at the injection site and innate immune activation [85].”
BackgroundAAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Gardner, M. R., Fellinger, C. H., Kattenhorn, L. M., Davis-Gardner, M. E., Weber, J. A., Alfant, B., Zhou, A. S., Prasad, N. R., Kondur, H. R., Newton, W. A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5409 · Cited by 52
Self-citation
Metadata
- Authors
- Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., Alter, G., McDermott, A. B., Mascola, J. R., & Roederer, M.
- Affiliations
- National Institutes of Health (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Welles, Hugh C.
- Jennewein, Madeleine F.
- Mason, Rosemarie D.
- Narpala, Sandeep
- Wang, Lingshu
- Cheng, Cheng
- Zhang, Yi
- Todd, John-Paul
- Lifson, Jeffrey D.
- Balazs, Alejandro B.
- Alter, Galit
- McDermott, Adrian B.
- Mascola, John R.
- Roederer, Mario
- ORCID
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-12-05
- Volume
- 14
- Issue
- 12
- Pages
- e1007395
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6296672
- OpenAlex
- W2902838323
- Cited by
- 53
- References
- 73
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 5 · 2019: 8
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2018-12-17)
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Pathogens (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Frederick National Laboratory for Cancer Research
- National Institutes of Health (HHSN261200800001C)
- National Institute on Drug Abuse (DP2DA040254)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV8 vector, gene therapy, passive immunization, rhesus monkeys, intrarectal challenge, HIV prevention, glycosylation, nonhuman primate model
- MeSH terms
- Dependovirus, Animals, Antibodies, Monoclonal, Antibodies, Viral, Genetic Vectors, Immunization, Passive, Macaca mulatta, Viral Envelope Proteins, Simian Immunodeficiency Virus, Genetic Therapy, Simian Acquired Immunodeficiency Syndrome, SAIDS Vaccines, Transgenes, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.